Canagliflozin and Cardiovascular disease- results of the CANVAS trial

• Main Authors: Syed Raza Shah (Author), Najla Issa Najim (Author), Zainab Abbasi (Author), Mazia Fatima (Author), Ayesha Altaf Jangda (Author), Waqas Shahnawaz (Author), Maira Shahid (Author), Syed Arbab Shah (Author)
• Format: Book
• Published: Greater Baltimore Medical Center, 2018-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Canagliflozin is a new novel oral antidiabetic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, inhibiting glucose reabsorption in the proximal tubule, leading to increased urinary glucose excretion and subsequently to reduction in plasma glucose concentration, in...